Evidence map›Paper›PMID 41025648›Full record

ArticleAntimicrobial agents and chemotherapy2025

Sterilizing activity of spectinamide MBX-4888A when replacing linezolid in the Nix-TB regimen in the relapsing BALB/c mouse model of tuberculosis.

Nathan Peroutka-Bigus, Michael S Scherman, Firat Kaya, Samanthi L Waidyarachchi, Jiuyu Liu, Joel N Rushefsky, Michelle M Butler, Terry Bowlin, Bernd Meibohm, Mercedes Gonzalez-Juarrero and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Nathan Peroutka-BigusMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.ORCID 0000-0001-5212-9541
Michael S SchermanMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Firat KayaCenter for Discovery and Innovation, Hackensack Meridian School of Medicine, Nutley, New Jersey, USA.
Samanthi L WaidyarachchiMicrobiotix, Inc., Worcester, Massachusetts, USA.
Jiuyu LiuDepartment of Chemical Biology & Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Joel N RushefskyMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Michelle M ButlerMicrobiotix, Inc., Worcester, Massachusetts, USA.
Terry BowlinMicrobiotix, Inc., Worcester, Massachusetts, USA.ORCID 0000-0002-9184-5791
Bernd MeibohmDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, Tennessee, USA.ORCID 0000-0003-3923-3648
Mercedes Gonzalez-JuarreroMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.ORCID 0000-0002-4045-2365
Anne J LenaertsMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Matthew ZimmermanCenter for Discovery and Innovation, Hackensack Meridian School of Medicine, Nutley, New Jersey, USA.
Richard E LeeDepartment of Chemical Biology & Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.ORCID 0000-0002-2397-0443
Gregory T RobertsonMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.ORCID 0000-0001-7157-4034

Funding

Development of Novel Proteins Synthesis Inhibitors for MDR TuberculosisR01AI090810 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI LEE, RICHARD E. · 2010 to 2022
$8.9M
Novel Spectinamide Antibiotics for the Treatment of MDR/XDR TuberculosisR44AI098271 · NIAID · MICROBIOTIX, INC · PI BUTLER, MICHELLE M. · 2014 to 2021
$6.0M
NIAID NIH HHS R01 AI090810NIAID NIH HHS R44 AI098271NIH HHS R01AI090810NIH HHS R44AI098271
6 · The paper itself

Abstract

Spectinamides have garnered interest as experimental tuberculosis therapeutics owing to their safety profile and efficacy as partner agents when used in conjunction with established regimens in mice. The Nix-TB regimen of bedaquiline, pretomanid, and linezolid represents a short, effective regimen recommended for treatment of pre-extensively drug-resistant tuberculosis. However, linezolid administration is associated with severe adverse events that limit its use. Here we present preclinical data comparing Nix-TB regimens anchored by either linezolid or spectinamide MBX-4888A.

Indexed as

Antitubercular AgentsLinezolidMycobacterium tuberculosisNitroimidazolesSpectinomycinAdamantaneAnimalsDiarylquinolinesDisease Models, AnimalDrug Therapy, CombinationEthylenediaminesFemaleMiceMice, Inbred BALB CMicrobial Sensitivity TestsAdamantaneAntitubercular AgentsbedaquilineDiarylquinolinesEthylenediaminesLinezolidN-geranyl-N'-(2-adamantyl)ethane-1,2-diamineNitroimidazolespretomanidSpectinomycinBALB/cbedaquilinepretomanidrelapsespectinamidetuberculosis

Identifiers

PMID41025648
PMCPMC12587623

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.